Ring Therapeutics

Founded by @FlagshipPioneer, Ring is powering a new era of gene therapy

[Ring Therapeutics @ring_tx]

Today @FlagshipPioneer unveiled our company! Developing first-in-class gene therapies using a new viral vector platform based on our pioneering work on the human commensal virome. Learn more at https://t.co/ncxf5pTFdB

[Ring Therapeutics @ring_tx]

New data at #ASGCT2025 on our AnelloBricks® platform! This in vitro approach to producing functional anellovirus vectors has the potential to offer many advantages in manufacturing compared to existing vector systems. Read more and attend our talk: https://t.co/dvfbgZb0E4

[Ring Therapeutics @ring_tx]

Mark your calendars - we'll be at #ASGCT2025! Come say hello and check out our presentations highlighting new data from our #Anellogy platform. See you in New Orleans!

[Ring Therapeutics @ring_tx]

#ICYMI our CTO Konstantin Konstantinov, Ph.D., recently spoke with @lifesci_connect, highlighting our novel AnelloBricks platform as a potentially transformative solution for the #GeneticMedicines space. Learn more here: https://t.co/S6ZUfqM8NH

[Ring Therapeutics @ring_tx]

Our exciting partnership announcement was just featured in @FierceBiotech, highlighting our continued efforts in supporting the flourishing biotech ecosystem in the Singapore region and the advancement of our novel Anellogy™ platform. Read here: https://t.co/2SwvBaRXbJ

[Ring Therapeutics @ring_tx]

Excited to announce our new strategic partnership with @ASTARsg and the @snec_seri to advance innovative R&D efforts and support the continued development of the biomedical science ecosystem in the region. To learn more about the news, read here: https://t.co/ydBSAIjAV1

[Ring Therapeutics @ring_tx]

We're attending #ESGCT2024 where we're showcasing successful genomic payload expansion of our novel AnelloVector, further validating it as the first gene delivery vector system based on the human commensal anellovirus. Learn more here: https://t.co/Kl953R7xJY

[Ring Therapeutics @ring_tx]

Our CTO, Konstantin Konstantinov, will be delivering the opening keynote lecture at the upcoming SPICA conference, discussing the latest breakthroughs across the Preparative and Industrial Chromatography field aiming to advance #GeneticMedicine. More: https://t.co/0c9VfYTZHe

[Ring Therapeutics @ring_tx]

At Ring, our values drive our team of pioneers forward. Together as #OneRing, we are dedicated to fostering an audacious, inclusive, and resilient culture as we work to build a better future for patients.

[Ring Therapeutics @ring_tx]

#DYK our Anellovectors can be engineered to have an expanded payload capacity beyond natural anellovirus genome sizes? Data presented at #ASGCT2024 unveiled the broadened therapeutic potential of this novel class of viral vectors across diseases. More: https://t.co/sCdKAvzGmB

[Ring Therapeutics @ring_tx]

Thrilled to share our recent publication in @NatureComms on the unique structure of anelloviruses, the foundation of our Anellogy™ platform. Learn how their structure enables immune evasion and how anelloviruses are transforming #GeneticMedicine: https://t.co/mPxeJ5NCyz

[Ring Therapeutics @ring_tx]

Check out the latest episode of @CGT_Live where our Chief Medical Officer and Head of Translational Research, Chris Wright, MD, PhD, discussed our latest data findings on anelloviruses and the promise they hold to revolutionize #GeneTherapy. Watch here: https://t.co/mR0ncebx38

[Ring Therapeutics @ring_tx]

🧬🔬 Happy #NationalInternDay! Our co-ops are helping us push the boundaries of what is possible and we’re so thankful for their hard work and dedication to the team. The future of #biotech is bright, and we can’t wait to see where these #FutureLeaders end up.

[Ring Therapeutics @ring_tx]

🏓 Last month, our team swapped lab coats for paddles and had a blast on the #Pickleball court for our summer outing. It was an evening full of games, laughs, and celebrations in honor of our 7th anniversary! Check out these photos from the event!

[Ring Therapeutics @ring_tx]

Earlier this month, we closed our offices for a #SummerShutdown to allow our team to rest, rejuvenate, & participate in summer activities that matter to them! We prioritize a work-life-balance so our team can continue their hard work toward revolutionizing programmable medicines.

[Ring Therapeutics @ring_tx]

Exciting news from @FlagshipPioneer as they announce the raise of $3.6 billion to fuel breakthrough innovations to transform human health and sustainability. We are proud to be #FlagshipFounded and part of an ecosystem of companies taking bold scientific leaps for a better future

[Flagship Pioneering @FlagshipPioneer]

Flagship Pioneering raises $3.6 billion to fuel critical breakthroughs in human health and sustainability. This expanded capital pool will accelerate the impact of original science and the creation and development of an estimated 25 breakthrough companies in human health, sustainability, and artificial intelligence. Hear from Flagship Founder and CEO @NoubarAfeyan about how we're taking #BiggerLeaps by leveraging the power of generative AI, forging novel partnerships with pharma to speed drug development, expanding globally, and promoting and hiring top talent to our leadership ranks. ​Read the full press release: https://t.co/uQt9hWJ6r0

[Ring Therapeutics @ring_tx]

#DYK most people already have antibodies to AAVs, limiting accessibility of current gene therapies? Unlike AAVs, Anelloviruses don’t elicit a robust immune response, enabling Anellovectors to deliver #GeneticMedicine to almost anyone. Learn more: https://t.co/EwBLF4Wvxc

[Ring Therapeutics @ring_tx]

#ICYMI we presented new preclinical data on our Anellovectors at #ASGCT2024! It was an exciting opportunity to be on the ground with other #biotech experts & share our unique approach to transforming #GeneticMedicine. Dive deeper into our presentations: https://t.co/RKiPbKr5VP

[Ring Therapeutics @ring_tx]

It was exciting to present at #ASGCT2024 alongside these other #FlagshipFounded companies! Check out the full summary and highlights to learn more about the redosability of our novel Anellovector, a new class of viral vector.

[Flagship Pioneering @FlagshipPioneer]

Flagship-founded companies joined other leaders in #cellandgenetherapy at the @ASGCTherapy's Annual Meeting, sharing strides in the development of their respective bioplatform technologies and progress toward potentially transformative medicines. Read the full summary and highlights below: https://t.co/xXrKO5jVUR

🔷 @ring_tx shared data in nonhuman primates showing the ability to redose genetic medicines using their vectors based on a little-known class of viruses called anelloviruses.
🔷 @TesseraTx displayed curative results in humanized mouse models using its Gene Writers and proprietary lipid nanoparticles to restore normal hemoglobin production in hematopoietic stem cells in the bone marrow without chemotherapy or mobilization for the treatment of #sicklecelldisease.
🔷 @alltrna demonstrated robust ability to readthrough premature stop codons in mouse models, promising preclinical results that suggest their engineered tRNAs could offer a versatile approach to rescue protein production in rare and ulta-rare diseases caused by nonsense mutations, known as stop codon disease.
🔷 @OmegaTX showed preclinical data highlighting their ability to program epigenetic controllers to upregulate gene expression for a variety of genes types and cell conditions, providing effects that last weeks to months after a single dose.
🔷 Sana Biotechnology displayed data showing a promising safety profile for their in vivo CAR T therapy, suggesting its potential to offer comparable efficacy and genomic safety as established treatments.

[Ring Therapeutics @ring_tx]

Stemming from our new data at #ASGCT2024, Tuyen Ong, CEO, was featured in a @FierceBiotech article spotlighting our Anellovector, a new class of viral vector, and it’s promise of redosability compared to traditional AAVs. Read about it here: https://t.co/rG7Moniavt

[Ring Therapeutics @ring_tx]

#DYK #Anelloviruses demonstrate immune favorability? This unique privilege to evade the immune system enables our vectors made from anelloviruses to deliver #GeneticMedicine without causing a robust immune response. Discover more here: https://t.co/CKaiUhPTcg #AnelloInsights